FDA Yanks Drug Approval: Lies and Lies in Medicine's Pipeline?
Published Date: 4/30/2026
Notice
Summary
The FDA wants to take back its approval of the drug TAVNEOS, made by ChemoCentryx, because new info shows it might not work as promised and some facts in the application weren’t true. ChemoCentryx can ask for a hearing by June 1, 2026, to defend their drug. This could affect patients using TAVNEOS and might shake up the company’s plans and finances.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
FDA Proposes Withdrawal of TAVNEOS Approval
The FDA is proposing to withdraw approval of TAVNEOS (avacopan) capsule, 10 mg, which the agency originally approved on October 7, 2021 for adjunctive treatment of adult patients with severe active ANCA-associated vasculitis. The agency's grounds are that new information shows manipulated study data and untrue statements of material fact, so there is a lack of substantial evidence that the drug is effective under the labeled conditions.
Postmarket Safety Signals: Liver Risks
FDA identified hepatotoxicity as a key safety risk for avacopan and noted serious and sometimes fatal hepatotoxicity cases reported after approval. Recent postmarketing safety reports also suggest avacopan may be associated with vanishing bile duct syndrome (VBDS), an unexpected serious adverse event.
Hearing and Comment Deadlines Set
ChemoCentryx (the applicant) may request a hearing on the proposed withdrawal by June 1, 2026, and must submit all data and analyses supporting a hearing request by June 29, 2026. Other interested parties may submit electronic or written comments by June 29, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-08454, New England Fishery Management Council; Public Meeting
The New England Fishery Management Council is holding a public webinar on May 14, 2026, to discuss important rules for local fishermen, especially about scallops and redfish. They’ll talk about gear rules and fishing area conflicts that could affect how and where fishing happens. This meeting helps make sure fishing stays fair and sustainable, with no immediate costs but big impacts on fishing practices.
Next: 2026-08456, Proposed Collection; 60-Day Comment Request; NIH Office of Intramural Training & Education-Application, Registration, and Alumni Systems Office of the Director
The NIH Office of Intramural Training & Education wants your feedback on updating their application, registration, and alumni systems. This affects students, trainees, and alumni who use these systems and aims to make things smoother and easier. Comments are open for 60 days, so jump in now to help shape the future—no extra costs involved!